Recombinant Human CGRP protein

**Background of Recombinant CGRP Protein**

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide widely distributed in the central and peripheral nervous systems. It exists in two isoforms, α-CGRP and β-CGRP, with α-CGRP primarily expressed in sensory neurons and β-CGRP in enteric neurons. CGRP plays critical roles in vasodilation, pain modulation, inflammation, and neurogenic responses. Its involvement in migraine pathophysiology, particularly through vasodilation and nociceptive signaling, has made it a key therapeutic target.

Recombinant CGRP protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems. This technology enables large-scale production of high-purity CGRP for research and clinical applications. Recombinant CGRP retains biological activity, allowing scientists to study its receptor interactions (e.g., with CLR/RAMP1 complexes) and downstream pathways (e.g., cAMP signaling). It is also used to develop antibodies or small-molecule inhibitors, such as CGRP receptor antagonists (gepants) and monoclonal antibodies (e.g., erenumab), which are FDA-approved for migraine prevention.

Beyond migraines, recombinant CGRP is investigated in cardiovascular diseases, wound healing, and bone metabolism due to its vasoprotective and trophic effects. However, challenges remain, including optimizing stability, delivery methods, and minimizing off-target effects. Advances in protein engineering, such as site-specific PEGylation or fusion proteins, aim to enhance its therapeutic potential.

In summary, recombinant CGRP protein serves as a vital tool for understanding neuropeptide biology and developing targeted therapies, reflecting the intersection of neuroscience, molecular biology, and clinical medicine.